Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Xiao Zhou
Beth Israel Deaconess Medical Center, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Pinteon Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Pinteon Therapeutics, Inc. has licensed a specified subset of patents related to Pin1. The research results validating of the role of early pathogenic cis pT231-tau as a new drug target, and the evaluation of the efficacy of a novel class of drugs in inhibiting tauopthy and halting cognitive decline relevant to Alzheimer’s disease would be useful in advancing compounds into preclinical development for Alzheimer’s disease. The he investigator’s significant financial interest could directly and significantly affect the design, conduct, or reporting of the PHS-funded research. Therefore, BIDMC has determined that the private equity interest constitutes a financial conflict of interest with the research for this grant under applicable PHS regulations (45 C.F.R. §50.601 et seq.).
Drug Discovery against the Early, Secreted and Toxic Tau in Alzheimer's Disease
The prevalence of Alzheimer's disease increases rapidly as people live longer, but currently there is no effective treatment. Since Alzheimer's disease may take more than a decade to develop, therapies that specifically target early pathogenic events are sorely needed for this devastating disease. As a proof of concept, we have discovered [the early, secreted and toxic tau that leads to tau pathology and memory loss in Alzheimer's disease, and here describe the development of innovative neutralizing antibodies and vaccines specifically against only this early, secreted and toxic tau] while leaving healthy tau untouched to inhibit tau pathology and halt memory loss at an early step for treating Alzheimer's disease. We believe that these studies might lead to a novel class of immunotherapy for Alzheimer's disease.
Filed on April 14, 2015.
Tell us what you know about Xiao Zhou's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Xiao Zhou”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Xiao Zhou | Beth Israel Deaconess Medical Center | Conflict of Interest | Pinteon Therapeutics, Inc. | Value cannot be readily determined |
| Xiao Zhou | Beth Israel Deaconess Medical Center | Conflict of Interest | Pinteon Therapeutics, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.